- Home
- SCLXW vs SCD Comparison
SCLXW vs SCD Comparison
Compare SCLXW & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- SCD
- Stock Information
- Founded
- SCLXW N/A
- SCD 2003
- Country
- SCLXW United States
- SCD United States
- Employees
- SCLXW 113
- SCD N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- SCD Trusts Except Educational Religious and Charitable
- Sector
- SCLXW Health Care
- SCD Finance
- Exchange
- SCLXW Nasdaq
- SCD Nasdaq
- Market Cap
- SCLXW N/A
- SCD N/A
- IPO Year
- SCLXW 2021
- SCD N/A
- Fundamental
- Price
- SCLXW $0.24
- SCD $17.40
- Analyst Decision
- SCLXW
- SCD
- Analyst Count
- SCLXW 0
- SCD 0
- Target Price
- SCLXW N/A
- SCD N/A
- AVG Volume (30 Days)
- SCLXW N/A
- SCD 62.6K
- Earning Date
- SCLXW N/A
- SCD 01-01-0001
- Dividend Yield
- SCLXW N/A
- SCD 9.63%
- EPS Growth
- SCLXW N/A
- SCD N/A
- EPS
- SCLXW N/A
- SCD N/A
- Revenue
- SCLXW N/A
- SCD N/A
- Revenue This Year
- SCLXW N/A
- SCD N/A
- Revenue Next Year
- SCLXW N/A
- SCD N/A
- P/E Ratio
- SCLXW N/A
- SCD N/A
- Revenue Growth
- SCLXW N/A
- SCD N/A
- 52 Week Low
- SCLXW N/A
- SCD $11.33
- 52 Week High
- SCLXW N/A
- SCD $15.87
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- SCD 58.85
- Support Level
- SCLXW N/A
- SCD $16.34
- Resistance Level
- SCLXW N/A
- SCD $17.20
- Average True Range (ATR)
- SCLXW 0.00
- SCD 0.42
- MACD
- SCLXW 0.00
- SCD 0.04
- Stochastic Oscillator
- SCLXW 0.00
- SCD 91.38
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.